Ovarian cancer revealed by paraneoplastic cerebellar degeneration: a case report

Abstract

The prevalence of paraneoplastic cerebellar degeneration (PCD) associated with gynecological cancer is rare. Here, we reported the first case of ovarian cancer revealed by PCD in our institute. we describe a 80- year –old Moroccan female presented with subacute vestibular and cerebellar syndromes, she had an inguinal lymphadenopathy,with high levels of Anti-YO. Rapid progression and absence of known etiologies point towards a probable paraneoplastic origin of the syndrome in this patient. The exact incidence of PNS among those diagnosed with cancer remains uncertain, it is important to report this cases in the literature to help early diagnosis and appropriate treatment, which are able to stabilize the neurological symptoms.

Paraneoplastic cerebellar degeneration heralding recurrence of fallopian tube adenocarcinoma: A case report and literature review

“…PCD has been described prior to the appearance of primary tumor in fallopian tube carcinomas, however, there have been no reports of PCD heralding a recurrence in fallopian tube carcinomas. On average, time between a patient's initial symptoms and the diagnosis of PCD and subsequent cancer diagnosis is 2.7 months with a range of 2 weeks–13 months ( Negishi, 2014 , O'Brien et al, 1995 , Matuchita, 1998 , Levite et al, 2001 , Tanaka, 2005 , Selby, 2011 , Russo et al, 2013 , López et al, 2013 , Haggerty et al, 2015 , Elomrani, 2014 , Saeed and Gupta, 2014 , Kumari, 2014 , Li, 2015 , Chien et al, 2015 , Cui et al, 2017 , Renjen et al, 2018 ). In gynecological cancers, initial symptoms are most commonly vertigo, gait instability, and dysarthria.…”

Gynecologic clear cell carcinoma and paraneoplastic cerebellar Degeneration: A literature review and case study

“…Table 1 highlights the previously reported primary gynecologic malignancies associated with PCD, along with patient symptoms, imaging findings, and outcomes ( Cao et al, 1999 , Liontos et al, 2021 , Marchand et al, 2007 , Campero and Selman, 2017 , Tanaka et al, 2005 , Johns et al, 1999 , Erez et al, 2007 , Juárez-Vignon Whaley et al, 2021 , Elomrani et al, 2014 , Negishi et al, 2014 , Panegyres and Graves, 2012 , Russo et al, 2013 , Butt et al, 2019 ). Here, we present a patient diagnosed with PCD in the setting of gynecologic clear cell carcinoma and highlight how symptomatology and neurologic outcomes in this disease process may be associated and provide clinicians with management considerations.…”